Blood pressure treatment target in patients with diabetes mellitus - Current evidence

Annals of Medicine

Volumn 44, Issue SUPPL. 1, 2012, Pages

  Barengo, Noël C ^a,b   Tuomilehto, Jaakko O ^c,d  

^a UNIVERSITY OF OULU   (Finland)

^b Fundacion para Prevencion Control Enfermedades Cronicas No Transmisibles America Latina (FunPRECAL)   (Argentina)

^c SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^d DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Diabetes mellitus; diastolic blood pressure; evidence; patients; systolic blood pressure; treatment

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 84862562489     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.679961     Document Type: Review

References (40)

1. International Diabetes Federation (IDF). Diabetes atlas. 4th edition. Brussels: IDF; 2009.
2. Finnish Diabetes Association. Program for the prevention of type 2 diabetes in Finland 2003-2010. Jyväskylä, Finland: Gummerus; 2003.
3. Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care. 1998;21:539-45. (Pubitemid 28172931)
4. Tuomilehto J, Rastenyte D, Qiao Q, Jakovljevic D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In: De Fronso RA, Ferrannini E, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. 3rd ed. Milan: John Wiley & Sons; 2004. p. 1345-70.
5. Manuel D, Schultz S. Health-related quality of life and health-adjusted life expectancy of people with diabetes mellitus in Ontario, Canada, 1996-1997. Diabetes Care. 2004;27:407-14. (Pubitemid 38174065)
6. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22. [Erratum, Lancet. 2010;376:958].
7. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44. (Pubitemid 23046633)
8. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, Ford ES, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol. 2004;160:531-39. (Pubitemid 39215629)
9. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42. (Pubitemid 38101606)
10. Cheung BMY, Ong KL, Cherny SS, Sham PC, Tso AWK, Lam KSL. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-53.
11. Wang J, Geiss LS, Cheng YJ, Imeratore G, Saydash SH, James C, et al. Long-term and recent progress in blood pressure levels among U.S. adults with diagnosed diabetes, 1988-2008. Diabetes Care. 2011;34:1579-81.
12. N ilsson PM, Cederholm J, Zethelius B, Eliasson B, Eeg-Olofsson K, Gudbjörnsdottir S. Trends in blood pressure control in patients with type 2 diabetes-Data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20:348-54.
13. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87. (Pubitemid 46924065)
14. Guidelines Sub-Committee. 1999 World Health Organization/International Society of Hypertension Guidelines for the management of hypertension. J Hypertens. 1999;17:151-83.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
16. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-88. (Pubitemid 46842793)
17. Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, et al. Latin America Expert Group. Latin American Guidelines on Hypertension. J Hypertens. 2009;27:905-22.
18. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
19. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1-40.
20. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-2.
21. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S11-61.
22. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.
23. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27:415-33.
24. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOTStudy Group. Lancet. 1998;351:1755-62. (Pubitemid 28269185)
25. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.
26. Deedwania PC. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go? Circulation. 2011;123:2776-8.
27. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92. [Erratum, JAMA. 1997;277:1356.] (Pubitemid 26419185)
28. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al., for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-84. (Pubitemid 29110751)
29. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulbitt CJ, Clement D, et al.; and Syst-Eur Investigators. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Investigators. Circulation. 2000;102:1139-44.
30. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54-64. (Pubitemid 30185779)
31. Weber M, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56:77-85.
32. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.
33. ACCORD Study Group, Cushman W, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362;1575-85.
34. McAlister FA, Zarnke KB, Campbell NRC, Feldman RD, Levine M, Mahon J, et al. The 2001 Canadian recommendations for the management of hypertension: part 2, therapy. Can J Cardiol. 2002;18:625-41.
35. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
36. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W; VADT Study Group. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2011;34:34-8.
37. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R; INVEST Investigators. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study. Hypertension. 2004;44:637-42. (Pubitemid 39435232)
38. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analysis of randomized trials. Circulation. 2011;123:2799-10.
39. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens. 2011:29:1253-69.
40. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;23:2837-40.